Pilomyxoid astrocytoma

Pilomyxoid astrocytoma (PMA) is a rare brain tumor classified as a variant of pilocytic astrocytoma, primarily affecting the central nervous system. It was recognized as a distinct entity by the World Health Organization (WHO) and historically graded as WHO grade II, though more recent classifications have reconsidered its grading. PMA most commonly arises in the hypothalamic/chiasmatic region of the brain, though it can occur in other locations including the cerebellum, temporal lobe, brainstem, and spinal cord. The tumor is characterized by a distinctive histological appearance featuring monomorphous bipolar cells set within a prominent myxoid (mucin-rich) background, lacking the Rosenthal fibers and eosinophilic granular bodies typically seen in classic pilocytic astrocytomas. Pilomyxoid astrocytoma predominantly affects young children, with a median age of onset around 18 months, though it can occur at any age. Key symptoms depend on tumor location but commonly include signs of increased intracranial pressure such as headaches, nausea, vomiting, and in infants, increasing head circumference (macrocephaly) and bulging fontanelle. Visual disturbances, failure to thrive, developmental delay, and endocrine abnormalities (particularly related to hypothalamic-pituitary dysfunction) are frequently observed. PMA tends to behave more aggressively than classic pilocytic astrocytoma, with higher rates of local recurrence and a greater propensity for cerebrospinal fluid dissemination (leptomeningeal spread). Treatment typically involves surgical resection when feasible, though complete resection is often difficult due to the tumor's predilection for deep midline structures. Chemotherapy is frequently employed, particularly in young children, to delay or avoid radiation therapy. Common chemotherapy regimens include carboplatin and vincristine combinations. Radiation therapy may be considered for older children and adults with recurrent or progressive disease. Despite treatment, pilomyxoid astrocytomas carry a less favorable prognosis compared to classic pilocytic astrocytomas, with higher recurrence rates and shorter progression-free survival. Some tumors may mature over time into classic pilocytic astrocytomas, which may be associated with improved outcomes. An association with neurofibromatosis type 1 (NF1) has been reported in some cases. Long-term multidisciplinary follow-up involving neurosurgery, oncology, endocrinology, and ophthalmology is essential.

Common questions about Pilomyxoid astrocytoma